GAS5 lncRNA: A biomarker and therapeutic target in breast cancer

• Published in: Pathology, research and practice Vol. 260; p. 155424
• Main Authors: Thangavelu, Lakshmi, Moglad, Ehssan, Gupta, Gaurav, Menon, Soumya V., Gaur, Ashish, Sharma, Snehlata, Kaur, Mandeep, Chahar, Mamata, Sivaprasad, G.V., Deorari, Mahamedha
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-08-2024
• Subjects: Apoptosis; Breast cancer; EMT; GAS5; Prognostic biomarker; Tumor aggressiveness; Tumor aggressiveness; Breast cancer; GAS5; EMT; Apoptosis; Prognostic biomarker
• ISSN: 0344-0338; 1618-0631; 1618-0631
• DOI: 10.1016/j.prp.2024.155424

Breast cancer is one of the most common causes of cancer-related mortality globally, and its aggressive phenotype results in poor treatment outcomes. Growth Arrest-Specific 5 long non-coding RNA has attracted considerable attention due to its pivotal function in apoptosis regulation and tumor aggressiveness in breast cancer. Gas5 enhances apoptosis by regulating apoptotic proteins, such as caspases and BCL2 family proteins, and the sensitivity of BCCs to chemotherapeutic agents. At the same time, low levels of GAS5 increased invasion, metastasis, and overall tumor aggressiveness. GAS5 also regulates EMT markers, critical for cancer metastasis, and influences tumor cell proliferation by regulating various signaling components. As a result, GAS5 can be restored to suppress tumor development as a possible therapeutic strategy, which might present promising prospects for a patient’s treatment. Its activity levels might also be a crucial indicator and diagnostic parameter for prediction. This review highlights the significant role of GAS5 in modulating apoptosis and tumor aggressiveness in breast cancer, emphasizing its potential as a therapeutic target for breast cancer treatment and management.